Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:buprenorphine
|
| gptkbp:approvalYear |
2010
|
| gptkbp:ATCCode |
N02AE01
|
| gptkbp:contraindication |
acute asthma
severe respiratory depression |
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_III_(US)
|
| gptkbp:countryOfOperation |
gptkb:Australia
gptkb:Canada gptkb:United_Kingdom gptkb:United_States |
| gptkbp:duration |
7 days
|
| gptkbp:form |
transdermal patch
10 mcg/h 15 mcg/h 20 mcg/h 5 mcg/h 7.5 mcg/h |
| gptkbp:halfLife |
~26 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Butrans
|
| gptkbp:indication |
chronic pain
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Purdue_Pharma
|
| gptkbp:mechanismOfAction |
antagonist at kappa-opioid receptor
partial agonist at mu-opioid receptor |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
transdermal
|
| gptkbp:sideEffect |
nausea
constipation dizziness headache |
| gptkbp:bfsParent |
gptkb:Buprenorphine
gptkb:Purdue_Pharma gptkb:buprenorphine |
| gptkbp:bfsLayer |
6
|